# Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer

> **NCT02549677** · PHASE4 · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 294 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Docetaxel
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT02549677
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02549677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02549677, "Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02549677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*